Calysta Energy™ Targets Natural Gas as Advantaged Feedstock for Transportation Fuels and Chemicals

  Calysta Energy™ Targets Natural Gas as Advantaged Feedstock for
  Transportation Fuels and Chemicals

                 Unmet Market Need Creates Global Opportunity

Business Wire

MENLO PARK, Calif. -- October 22, 2012

Calysta Energy™, a new company, today announced it has been established to use
natural gas, an advantaged feedstock, to develop new liquid transportation
fuels and high value chemicals that are cost-effective, scalable and reduce
environmental impact. Current technology approaches to creating new fuels and
chemicals have failed to achieve necessary market economics, creating a
significant worldwide market opportunity.

Calysta’s proprietary biological gas-to-liquids™ (BioGTL™) platform uses
methane, an energy-rich component of natural gas, as a new biological
feedstock that is virtually untapped as an energy source outside of heating
and electricity generation. Natural gas, one of the world’s most abundant
forms of energy, does not compete with food, land or water resources.

Alan Shaw, Ph.D, a veteran industrial biotechnology executive, is leading the
Calysta team as Chairman, President and Chief Executive Officer, partnered
with Josh Silverman, Ph.D., an innovative technology leader with broad
experience in biotechnology startup ventures, as Chief Scientific Officer. Dr.
Shaw joins Calysta from a decade as President and CEO of Codexis, a developer
of cost-advantaged processes for biochemical, biofuel and pharmaceutical
production with global customers including Merck, Pfizer, Chemtex and Raizen.
Dr. Silverman, who is also co-founder, established and led R&D partnerships
and product development collaborations for five biotechnology companies,
including Avidia through acquisition by Amgen.

“Natural gas is an abundant, ideal source of low-cost carbon, and global
natural gas production is expected to double in the next 30 years,” Dr. Shaw
said. “However, practical technology to efficiently capture its potential
beyond current usage has not been developed. Using our advanced biotechnology
platform, Calysta is focused on enabling creation of economical fuels and
chemicals from natural gas for the first time, addressing a global market

About Calysta’s BioGTL™ Technology

Calysta is focusing on development of methane as a new biological feedstock
for cost-competitive, scalable biofuels and chemicals production. Methane is
widely available from large domestic deposits of shale gas, as well as
landfills and other sources. Calysta’s BioGTL™ technology uses sophisticated
biological engineering to create valuable cost and performance advantages over
current biological and chemical processes. Using the BioGTL™ technology
platform, Calysta is developing proprietary organisms to economically convert
methane into liquid hydrocarbons, the building blocks of higher-value, easily
transportable fuels and chemicals.

About Natural Gas Supply

Worldwide, the IEA estimates that natural gas could account for more than 25
percent of global energy demand by 2035. Increased exploration and improved
technology have led to substantial new natural gas discoveries in recent
years. US natural gas reserves rose by 12% to 318 trillion cubic feet in 2010,
according the US Dept. of Energy. Natural gas reserves now exceed conventional
gas reserves in major countries including the US, Canada and China. Current
technology to convert natural gas to chemical building blocks required for
fuel and chemical production is cumbersome and impractical, creating a market
opportunity for new technology applications.

About Launch of Calysta Website & Advisory Board

Calysta Energy also announced the launch of its new website,, which contains further information on the company, its
technology and markets, and media resources. In addition, Calysta has formed a
prestigious Advisory Board of leading academic and industry experts in
biotechnology, biocatalysis and fuel and chemical development (see separate
release on the website).

About Calysta Energy

Calysta Energy, LLC., Menlo Park, CA., is developing a new biological
gas-to-liquids™ (BioGTL™) technology using methane – an energy-rich component
of natural gas – as a new biological feedstock for transportation fuels and
high value industrial chemicals. The company is a spinout of DNA 2.0, the
largest US-based provider of synthetic genes for industrial and academic use.
For more information, visit


for Calysta
Lyn Christenson
Calysta Media Information
650-492-6880, ext. 200
Press spacebar to pause and continue. Press esc to stop.